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Abstract
Background: A strong recommendation from a clinician is one
of the best predictors of human papillomavirus (HPV) vaccination
among adolescents, yet many clinicians do not provide effective
recommendations. The objective of this study was to understand
how the lack of school entry requirements for HPV vaccination
influences clinicians’ recommendations.
Design and Methods: Semi-structured interviews with a pur-
posive sample of 32 clinicians were conducted in 2015 in
Connecticut USA. Data were analysed using an iterative thematic
approach in 2016-2017.
Results: Many clinicians described presenting HPV vaccina-
tion as optional or non-urgent because it is not required for school
entry. This was noted to be different from how other required vac-
cines were discussed. Even strong recommendations were often
qualified by statements about the lack of requirements.
Furthermore, lack of requirements was often raised initially by
clinicians and not by parents. Many clinicians agreed that require-
ments would simplify the recommendation, but that parents may
not agree with requirements. Personal opinions about school entry
requirements were mixed.
Conclusions: The current lack of school entry requirements
for HPV vaccination is an important influence on clinicians’ rec-
ommendations that are often framed as optional or non-urgent.
Efforts are needed to strengthen the quality of clinicians’ recom-
mendations in a way that remains strong and focused on disease
prevention yet uncoupled from the lack of requirements that may
encourage delays. Additionally, greater support for requirements
among clinicians may be needed to successfully enact require-
ments in the future.
Introduction
Human papillomavirus (HPV) infection is an established
risk factor for cancers of the anogenital tract and the orophar-
ynx.1 Vaccines against HPV are safe, effective, and have
demonstrated population-level impacts on reducing HPV infec-
tions and associated diseases in many countries,2,3 yet coverage
remains low in the United States (US) more than a decade after
their introduction. In 2016, only 50% of girls and 38% of boys
aged 13-17 years were up-to-date with the national Advisory
Committee on Immunization Practices’ (ACIP) recommended
HPV vaccination series, far below the Healthy People 2020
goals of 80%.4 This is in contrast to coverage rates of 88% for
tetanus/diphtheria/pertussis (Tdap) and 82% for meningococcal
(MCV4) vaccines that share the same ACIP recommendation
for routine administration at ages 11-12 years.4 Furthermore,
HPV vaccination coverage is lower in the US than in many
other developed countries: for example, countries in Northern
Europe, Australia, and New Zealand have collectively achieved
approximately 80% coverage with at least one dose among ado-
lescent females.5
A key difference between the US and other countries that
have achieved high coverage of HPV vaccination is their vac-
cine delivery systems. Countries such as Australia, Canada, and
England have all achieved high coverage, generally >80%,
through programs delivered in the context of universal health
care systems and often through regional or national school-
based programs that can reach a large number of children in a
relatively short period of time.6-8 In contrast, the US has neither
a national health care system nor a national school-based immu-
nization program. Rather, immunizations are typically delivered
in medical practices by primary care clinicians (practice-based
delivery). This fragmented delivery system creates multiple
possibilities for missed opportunities to immunization due to
numerous challenges including varied practice-based policies
and individual clinician beliefs and behaviours.
In a practice-based vaccination delivery system such as that
found in the US, a clinician’s recommendation for vaccination
is critically important. A strong recommendation from a clini-
cian for HPV vaccination has been consistently reported as one
of the most important facilitators of HPV vaccine uptake.9,10
However, research from the US has demonstrated that clinicians
often present HPV vaccine as optional or with less urgency than
other routinely recommended adolescent vaccines.11-15 Several
reasons for this have been identified. 
Clinicians may not provide effective recommendations
because of their own lack of knowledge about vaccine safety or
effectiveness, perceived lack of risk in their patients, and the
fact that they rarely see HPV-associated cancers in their patients
Significance for public health
More than a decade after its introduction, human papillomavirus (HPV) vacci-
nation coverage remains low in the United States despite a robust record of
safety and effectiveness. A strong recommendation from a clinician is one of
the most important determinants of uptake, yet clinicians often fail to provide
effective recommendations. One potential barrier to effective recommenda-
tions by clinicians that has not been explicitly studied is the widespread lack
of school entry requirements for HPV vaccination. In this qualitative study, we
found the lack of requirements to be an important reason for clinicians’ fram-
ing HPV vaccination recommendations as optional and non-urgent. Efforts are
needed to strengthen the quality of clinicians’ recommendations in a way that
is focused on disease prevention and uncoupled from requirements.
Additionally, greater support for HPV vaccination requirements among clini-
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because of the long delay between infection and development of
cancer.16,17 Clinicians may also be reluctant to discuss HPV vac-
cine with families because discussions may be perceived as
uncomfortable if the sexually transmitted nature of HPV arises
or clinicians may incorrectly assume that parents consider HPV
vaccination to be unimportant.14,18 Clinicians may also antici-
pate parents’ hesitancy due to parents’ perceived lack of knowl-
edge about the vaccine and safety concerns that could result in
time-consuming conversations.14
Within the US, a notable difference among the three recom-
mended vaccines for adolescents is the lack of widespread
requirements for HPV vaccination for middle school entry.
While ACIP recommendations are evidence-based, developed
through expert review, and reflect public health guidance, they
do not carry legal authority. On the other hand, state-level vac-
cination requirements for school entry are either administrative
regulations or statutory laws, though exemptions for medical,
religious, or philosophical reasons exist in most places. School
entry requirements, sometimes referred to as mandates, are a
widely used component of state vaccination policies for many
childhood vaccines, and they have played an important role in
both reducing the burden of diseases and in achieving more
equitable coverage.19,20 Yet ten years after recommendations for
routine vaccination for girls, only three jurisdictions out of 51,
all 50 states and District of Columbia, require HPV vaccination
for entry to middle school including the District of Columbia,
Rhode Island, and Virginia.21 In comparison, 50 jurisdictions
currently require Tdap vaccination and 31 jurisdictions require
MCV4 for middle school entry. Early efforts by some states to
require HPV vaccination for school entry, which occurred soon
after licensure and were considered politically and economically
motivated, raised controversy.22 These efforts also occurred
amidst substantial media coverage that fuelled debate about the
about the importance of individual liberties and government
control. It also raised concerns about requiring a vaccine for a
sexually transmitted infection that was not likely to be transmit-
ted in the school setting. Many of these sentiments have
remained to present day reflected in on-going limited public
support for school entry requirements.23,24
This qualitative study was conducted to understand clini-
cians’ experiences with recommending HPV vaccination in the
context of lack of school entry requirements. It also examined
how clinicians anticipated future requirements might change
their recommendations and/or acceptance by parents.
Furthermore, because clinician support for requirements will be
key to their enactment and successful implementation, their own
personal opinions about school entry requirements were elicited.
Design and Methods
Study sample
Qualitative methods were chosen for this study to provide
deeper insight into clinicians’ thoughts and opinions that underlie
their behaviours related to recommending HPV vaccination. This
study was conducted in Connecticut, a state without a school entry
requirement for HPV vaccination. Qualitative interviews were
conducted in 2015 with clinicians who provide immunizations to
adolescents. Clinicians were recruited through purposive sampling
to ensure representation of different types of practices (private
practice, hospital-based, and community clinics), specialties (pae-
diatrics and family medicine), and different regions of the state
(eight counties). This approach allowed us to capture a range of
opinions across these characteristics and to ensure no prevailing
theme would be missed. Clinicians were identified through profes-
sional networks and a state-wide database of active, practicing
clinicians. 
Data collection
A semi-structured interview guide was developed to elicit
information about general practices and experiences regarding
HPV vaccination. The guide also included a question and follow-
up probes related to school entry requirements for HPV vaccina-
tion (Table 1). The guide was reviewed by two clinician-
researchers, pilot tested with two clinicians (not included in the
sample), and subsequently revised. Interviews were conducted by
phone, audio recorded, and transcribed. 
Data analysis
Data analysis was conducted during 2016-2017 using an itera-
tive thematic approach.25 This analytic approach was selected to
identify key themes, or observed units of meaning, from the data
(interview transcripts) through an integrated process of text seg-
mentation, content coding, and theme identification. An initial cod-
ing guide was developed based on key topics in the interview guide
and applied to segments of the transcripts by three investigators.
Initial discrepancies in coding were resolved through discussion
until consensus was achieved. Subsequently, all transcripts were
coded by at least one member of the research team using Atlas.ti
software (Version 7.5.4). Code reports were generated for topics
related to school entry requirements, and the full research team
then identified, discussed, and refined emergent themes. Results
were examined by the clinicians’ practice setting classified into
three groups as follows: hospital-based clinic, federally qualified
health centre, or ≥50% public insurance (subsequently referred to
as public setting); 11-49% public insurance (mixed setting); and
≤10% public insurance (private setting). This practice setting char-
acteristic was deemed important to consider because of known dif-
ferences in HPV vaccination coverage by income.4 The study pro-
tocol was deemed exempt from review by the institutional review
board for human subjects research at Yale University, and all ethi-
cal principles regarding autonomy, respect, informed consent, con-
fidentiality, and data security were followed.
Results
A total of 32 clinicians completed interviews. A majority of the
sample was female (69%), and the median age was 55 years
(range: 31 to 75 years). Most of the sample was physicians (88%)
with fewer nurse practitioners (12%), and 88% were trained in pae-
diatrics and 12% trained in family medicine. Three-quarters of the
sample worked in private practice, and the remaining 25% worked
in either hospital-based clinics or community health centres. The
estimated percent of patients with public insurance was as follows:
31% reported 0-10%, 41% reported 11-49%, and 28% reported
>50%. Emergent themes are discussed below with illustrative
quotes presented in Tables 2-4.
Many clinicians acknowledged that lack of school entry
requirements led them to present HPV vaccination as recommend-
ed but not required. Some clinicians noted that because of the lack
of a school entry requirement, they made a different type of recom-
mendation for HPV vaccine than for Tdap or MCV4 vaccines.
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Noting that parents might not feel obliged to accept HPV vaccina-
tion, clinicians felt that the discussion around vaccination was dif-
ferent. One clinician remarked that HPV vaccination was offered
as a choice. These views were expressed by providers across the
range of practice settings.
Several clinicians described how they stated that HPV vaccina-
tion was not required for school in their initial presentation of the
vaccine, and not in response to the issue being raised by parents.
When asked the general question about how they usually intro-
duced HPV vaccination to parents, clinicians described offering
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Table 1. Sample questions from interview guide.
General questions about HPV vaccination                               1.    How do you usually offer HPV vaccine when you see an eligible patient? 
                                                                                                           2.    Does your recommendation for HPV vaccine differ from your recommendation
                                                                                                                  for other vaccines? Probe: If so, how?
                                                                                                           3.    In your opinion, what are the barriers to parents for vaccinating their children against HPV?
                                                                                                           4.    What do you think would help increase rates of HPV vaccination?
Questions specific to school entry requirements                1.    How would your experience offering HPV vaccine be different if HPV were mandated for school?
attendance                                                                                      Probe: Do you think a mandate would raise vaccination rates?
                                                                                                           Probe: In your opinion, do you think a mandate would be a good or bad policy move?
Table 2. Impact of lack of school entry requirement on recommendation for HPV vaccination.
Themes                                                         Illustrative quotes
Often results in a different type                               Well, it is [different], because I think the Menactra's required for school—for the middle school kids. 
of recommendation than for other vaccines          It's required for entry to college…It's something that has to go on the school form. (P4)
                                                                                           This [HPV vaccination] doesn't have that sense of obligation. The sell is a little different.
                                                                                           HPV is the only one that is offered as a choice. (P14)
                                                                                           Well, I say these are required and this one’s recommended. I mean, they could still go to seventh grade or
                                                                                           sixth grade…It’s not required. I tell them that. (P22)
Initial discussion sometimes leads with                 Oh, I say, ‘Well, we’d like to offer the HPV vaccine. It’s a recommended but not required vaccine.’ (P19)
statements about lack of requirement                    With their 11-year physical, we routinely introduce it. At the same time, we also have Tdap and Menactra that
                                                                                           are required. We say we have the HPV, and we say what it prevents; in girls, genital warts, and in boys −
                                                                                           in both girls and boys, genital warts, and in girls, cervical cancer. We tell them that it’s recommended. (P22)
Even strong recommendations are                          I’ll tell parents it’s not required for school, which it’s not, but that it’s - there’s a big health benefit, 
qualified by statements that it is not required      you know, it’s a carcinogenic virus. (P1)
                                                                                           When you're telling parents that, "Well, this [other vaccines] has to be done because it's required by the
                                                                                           state for school entry. The other one [HPV] isn't. It's an optional vaccine, but it is one we recommend." (P19)
                                                                                           Just they’re 11 now, there’s three vaccines we need to talk about. Two the school is gonna require and one
                                                                                           that we - isn’t required by school but we still think it’s a smart idea and we like to keep people healthy 
                                                                                           and this is what it is. It’s very straightforward. (P31)
Few clinicians discussed the                                      Because it is not a mandated vaccine, it often times takes parents a little longer to consent. 
need for longer conversations                                   ‘Here’s your Tdap, it’s required for school entry.’ It’s usually a very short conversation…For HPV, because it’s
                                                                                           not a mandated vaccine, it tends to involve more of a discussion. (P2)
Table 3. Anticipated impact of enacting a requirement on future recommendations.
Themes                                                    Illustrative quotes
Majority reported that recommendation          If we could start with ‘Here’s the HPV vaccine. It’s required prior to ninth grade.’, 
would be simplified and conversation               it would be much easier for parents. Parents in general don’t question it as much. (P12)
would be shortened                                               We can discuss what it’s for but the bottom line is they have to have it, so that makes it a lot easier. (P17)
                                                                                    I mean, we’d still have to - we have to talk about it anyway…But if it was required for school, maybe the people
                                                                                    who need to be convinced wouldn’t need to be convinced as much. We wouldn’t have to spend as much 
                                                                                    time trying to talk people into it. (P23)
Fewer reported conversation                              I think if it were mandated, it’s going to be, ‘You’re telling me to give my child a shot for a sexually transmitted
could become more difficult                               disease? Come on.’ It’s going to make people annoyed. (P1)
                                                                                    Yeah, I think the conversation would get longer. I think some of those families that don’t wanna do it, 
                                                                                    the conversation would go on and on. (P29)
Few also reported no change                              Because I treat all vaccines the same regardless of state requirements. I do what’s best for the patient. (P25)
                                                                                    The approach probably wouldn’t be any different. I’d still wanna explain why we want to do it as opposed to well,
                                                                                    school says you have to so we’re just gonna do ‘em and that’s it. (P31)
Requirement would increase parental              I think many of our parents are happy to do anything that they think they have to do.
acceptance, even if they disagreed                    Then they don’t have to think about it. (P8)
                                                                                    I think our adoption rate would go up significantly although we may have some frustrated or you know, aggravated
                                                                                    parents who disagree with it. I do think it would help. (P9)
                                                                                    They [parents] wouldn’t consider it optional any more, as optional as they seem to consider it now. (P10)
                                                                                    If HPV were a school requirement, I am pretty sure that people would go along with it. (P21)
                                                                                    I think it would [work]. I think you’d get a lot of grumpy people. (P27)
                                                                                   My own personal opinion, I think it sends them [parents] a strong message that this is important. (P28)
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the HPV vaccine as one that was recommended but not required.
In this way, it was often presented as an additional vaccine and one
that was separated from Tdap and MCV4 vaccines at the outset of
the conversation about the three immunizations that share the same
recommendation for routine administration at the same age of 11-
12 years. Often, this conversation occurred in an unsolicited man-
ner; that is, clinicians included this topic in the conversation not in
response to questions from parents.
Many clinicians expressed strong support for HPV vaccination
while at the same time describing how they qualified their recom-
mendation with statements about it not being required for school.
Clinicians often noted that HPV vaccination was important for pro-
viding excellent protection against cancers and that they supported
HPV vaccination for staying healthy, yet also mentioned that it was
an additional vaccine that was not required. 
A few clinicians felt that the lack of a requirement resulted in
the need for longer conversations with parents to obtain their
acceptance. Some clinicians noted that the lack of a requirement
resulted in parents taking more time to consent.
Clinicians expressed varied opinions about how their recom-
mendations for HPV vaccination would be different if school entry
requirements were enacted. Many clinicians felt that requirements
would shorten and simplify the recommendation. They recognized
that there was usually less discussion and fewer questions about
required immunizations, and that requirements made it easier for
some parents to accept vaccination. This sentiment was also
expressed by clinicians across the range of practice settings.
Notably, some clinicians acknowledged that conversation about
the vaccine would still be important.
Other clinicians described how the conversation could become
more difficult. Recognizing that HPV is not transmitted through
casual, non-intimate contact, some clinicians felt that they might
experience resistance from parents who would not agree with a
requirement for school entry. Specifically, it was noted that parents
might be annoyed by a requirement for vaccination against a sex-
ually transmitted infection. Relatively more clinicians from private
practices felt that the conversation would be more difficult and/or
lengthy due to push back from parents who might be offended by
the requirement. 
Few clinicians explained how their recommendations would
not change if there were a school requirement. These clinicians
remarked that all vaccines were treated the same, and that the ratio-
nale for all vaccines should be explained.
The majority of clinicians in all practice settings believed that
more parents would accept vaccination if it were required for
school entry. Some clinicians felt that this would directly remove
the sense of vaccination being optional. Other clinicians felt that
some parents would be happy to follow their clinicians’ recom-
mendations for a required vaccine without too much extra consid-
eration. Clinicians also felt that the recommendations would signal
the importance of HPV vaccination to parents. In response to the
general question about what would help to increase coverage,
some clinicians responded that school entry requirements were the
most obvious way to achieve this goal. 
Clinicians did discuss how a school requirement could have
different degrees of impact on coverage. Some felt that it would
help a relatively small number of patients, or just the more reluc-
tant families. Others felt that acceptance would go up significantly
and that it could help to vaccinate a large proportion of the popu-
lation. Even in the context of anticipated parental pushback, sever-
al clinicians described how a school requirement would still
increase coverage. Only one clinician expressed the dissenting
opinion that it would not make a substantial difference.
Clinicians’ own personal opinions about HPV vaccination
school entry requirements ranged the spectrum from positive to
negative. Some clinicians in both public and private settings
described being unequivocally in favour of requirements. Others
expressed their own personal support for a requirement but with
accompanying concerns about whether society was ready for such
a requirement, or whether it would be appropriate for everyone.
Some clinicians were more ambivalent in their attitudes about a
school requirement for HPV vaccine. A smaller number of clini-
cians, mostly in private practice, were not in favour of school
requirements. The main reason was concern about loss of parental
autonomy in making health care decisions. 
Discussion
Results of this study indicate that the current lack of middle
school entry requirements is a powerful influence on clinicians’
recommendations for HPV vaccination. This is significant because
a recommendation from a clinician is one of the most salient deter-
minants of HPV vaccine uptake.9,10 A high quality recommenda-
tions for HPV vaccination has been described as one that is strong
(emphasizing the importance of vaccination), urgent (recommend-
ing same-day vaccination), consistent (recommending vaccination
routinely), and timely (recommending vaccination by ages 11-12
years).15 Discussions about not needing HPV vaccination to attend
school may make this vaccine seem non-urgent, and thus could be
viewed as being of lower quality. Interestingly, many clinicians
provide strong recommendations, another component of a high-
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Table 4. Personal opinions.
Themes                                                         Illustrative quotes
In favour                                                                           It would absolutely be a positive change. (P23)
                                                                                            I would love that. (P26)
Mixed/ambivalent feelings                                           That [requirements] would be great, but mandates are tough…I don’t think we’ve got 
                                                                                            our ducks in a - I wasn’t necessarily embracing doing it now. I don’t think we’ve got our ducks in a row 
                                                                                            to do it. I’d hate to see it - I don’t want to see that effort fail if I didn’t really think we were ready. (P4)
                                                                                            I think parents may accept it more, may get more - more people - 
                                                                                            but I’m not sure if I agree that it should be mandated. (P18) 
                                                                                            Am I for it? In the general population, I’d say yes. But there would be exceptions. (P22)
                                                                                            I could see both sides. (P24)
Not in favour                                                                   It’s just doing things against their beliefs. I think a parent has the right to decide their -
                                                                                            to make their own decisions about the vaccine. (P6)
                                                                                            The less the government interferes with health care, the better. (P25)
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quality recommendation, by emphasizing its importance for pre-
venting cancer, while simultaneously conveying a lack of urgency.
Thus, in the current absence of requirements for HPV vaccination
for school entry in most places (48 out of 51 jurisdictions),
renewed efforts are needed to strengthen the quality of clinicians’
recommendations in a way that is strongly focused on cancer pre-
vention and uncoupled from lack of requirements that may encour-
age delays.
Several of the key findings from this study were expressed
across the range of practice types from public to private. For exam-
ple, statements were widespread that recommendations for HPV
vaccine were different from other vaccines due to lack of require-
ments, and that school requirements would increase coverage. On
other topics, however, differences emerged. The possibility that
longer conversations might be needed with parents who have con-
cerns about school requirements were largely raised by clinicians
who care mostly for privately insured patients. This may reflect
higher levels of vaccine hesitancy among this population.26
Clinicians in these practice environments may also feel greater fis-
cal pressures for more efficient visits from insurers and administra-
tors.27 These time pressures could be an important force in clini-
cians’ reluctance to engage in potentially lengthy conversations
about the need for HPV vaccination, and it could be further com-
pounded by different perceptions about the need for vaccination
based on suspected sexual activity.16 Efforts to work with clini-
cians to strengthen recommendations may need to address unique
situations in different practice settings.
Reasons for the widespread lack of requirements for HPV vac-
cination are complex and likely include the persistent reluctance of
states to revisit early efforts at enacting requirements that failed for
predominantly political reasons.28,29 If states consider enacting
requirements as a next step for increasing both coverage and equi-
ty, it will be important for legislators and policy makers to engage
with key stakeholder groups including clinicians who have the pri-
mary responsibility for immunizing children and adolescents, as
they will play an important role in this effort, both through their
support of enacting legislation and their subsequent efforts to
increase compliance with the new regulations.23 The mixed per-
sonal opinions and some degree of ambivalence among clinicians
about HPV vaccination requirements that were observed in this
study and previously reported by others indicate that efforts are
needed to build support for such a policy change to be success-
ful.24,30-32 Clearly, more than 10 years after vaccine introduction,
this hesitancy lingers despite the fact that requirements for other
adolescent vaccines were enacted well within 10 years in a major-
ity of jurisdictions.29
A key reason cited by clinicians in this study for not supporting
school entry requirements was related to valuing individual auton-
omy in decision making over government interference. In the case
of HPV vaccine, this sentiment may be even stronger because of
the perceived lack of risk of transmission in the school setting.
Activities to promote greater acceptance might include broad edu-
cational efforts targeted toward clinicians about how requirements
for other vaccines have greatly increased coverage and reduced
disparities.19,20,33 The recent experience in Rhode Island may sig-
nal the potential for requirements to increase coverage for HPV
vaccination specifically. In 2015, Rhode Island became the third
jurisdiction to pass a school entry requirement for HPV vaccina-
tion after Virginia and the District of Columbia enacted require-
ments in 2008 and 2009, respectively.21 After school entry require-
ments took effect, some public backlash occurred, but coverage
then increased in the following year from 76% to 90% in adoles-
cent girls and 69% to 88% in adolescent boys for at least 1 dose.34
Limitations
A key limitation of this study is the potential lack of generaliz-
ability. First, all clinicians were recruited from a single state and
there could be variability in views and opinions across other
regions of the US. Second, our sampling strategy did not capture
the full range of clinicians who provide immunizations (for exam-
ple, physician assistants), thus our results may not reveal the com-
plete landscape of views. Local data may be helpful in other areas
to fully inform clinician interventions and policy approaches going
forward. 
Conclusions
The current lack of school entry requirements for HPV vacci-
nation is an important influence on clinicians’ recommendations
that are often framed as optional or non-urgent. Efforts are needed
to strengthen the quality of clinicians’ current recommendations in
a way that is focused on prevention of cancer, inarguably an impor-
tant individual and public health goal, and uncoupled from the lack
of school entry requirements that may create a sense of non-urgen-
cy. Additionally, greater support for requirements among clinicians
may be needed to successfully enact school entry requirements in
the future. This may be a challenge for a vaccine that has raised
unique political and social debates, but likely a worthy goal to pro-
tect adolescents from future cancers.
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